Deutsche Bank Downgrades United Therapeutics Corp. (UTHR) to Hold; Oral Approval Likelihood Lowered

Deutsche Bank downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold.

Deutshce analyst says, "This morning United Therapeutics announced that the combination trial Freedom C(2) for Oral Remodulin did not hit primary endpoint. The improvement in 6MWD in the treatment group was only 10M, below our expectations. As a reminder, mono-therapy trial Freedom-M for Oral Remodulin did hit the primary end-point previously."

"We remain skeptical about the approval of oral Remodulin The co believes oral Remodulin can still get approved on Freedom-M data and expects to file in 1H2012. However, we remain cautious until we see detailed data from Freedom-M in 2012."

For more ratings news on United Therapeutics Corp. click here and for the rating history of United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $48.76 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Downgrades Qifu Technology (3660:HK) (QFIN) to Hold
• Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
• Deutsche Bank Downgrades Qifu Technology (QFIN) to Hold